Lobelia Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Lobelia Pharma
Largest movements
- Tangible fixed assets +€927,917
new in 2025: €927,917
- Receivables within one year +€134,428
up €134,428 (+572.1%), from €23,496 to €157,923
- Current investments +€109,971
up €109,971 (+36.7%), from €299,864 to €409,835
- Debts after one year +€793,383
up €793,383 (+75.6%), from €1.0m to €1.8m
of which Financial debts: +€793,383
- Reserves +€274,150
up €274,150 (+22.5%), from €1.2m to €1.5m
of which Distributable reserves: +€274,150
- Current portion of long-term debt +€79,901
up €79,901 (+196.1%), from €40,738 to €120,639
- Gross operating margin +€121,722
up €121,722 (+153.8%), from €79,128 to €200,850
- Depreciation +€94,688
new in 2025: €94,688
- Financial income +€12,419
up €12,419 (+5.3%), from €232,349 to €244,769
- Financial charges +€8,154
up €8,154 (+38.5%), from €21,189 to €29,343
- Taxes +€6,483
up €6,483 (+16.8%), from €38,652 to €45,135
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,374,480 | €3,546,134 | +€1.2m | +49.3% |
| Fixed assets | 21/28 | €2,025,000 | €2,952,917 | +€927,917 | +45.8% |
| Tangible fixed assets | 22/27 | - | €927,917 | +€927,917 | |
| Land and buildings | 22 | - | €927,917 | +€927,917 | |
| Financial fixed assets | 28 | €2,025,000 | €2,025,000 | = | 0.0% |
| Current assets | 29/58 | €349,480 | €593,217 | +€243,737 | +69.7% |
| Amounts receivable within one year | 40/41 | €23,496 | €157,923 | +€134,428 | +572.1% |
| Trade receivables | 40 | €23,496 | €157,923 | +€134,428 | +572.1% |
| Current investments | 50/53 | €299,864 | €409,835 | +€109,971 | +36.7% |
| Cash at bank and in hand | 54/58 | €24,759 | €25,459 | +€700 | +2.8% |
| Deferred charges and accrued income | 490/1 | €1,362 | - | -€1,362 | |
| Total equity and liabilities | 10/49 | €2,374,480 | €3,546,134 | +€1.2m | +49.3% |
| Equity | 10/15 | €1,240,502 | €1,514,663 | +€274,161 | +22.1% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,220,030 | €1,494,180 | +€274,150 | +22.5% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,860 | €1,860 | = | 0.0% |
| Distributable reserves | 133 | €1,218,170 | €1,492,320 | +€274,150 | +22.5% |
| Profit (loss) carried forward | 14 | €1,872 | €1,883 | +€11 | +0.6% |
| Amounts payable | 17/49 | €1,133,977 | €2,031,471 | +€897,493 | +79.1% |
| Amounts payable after more than one year | 17 | €1,049,284 | €1,842,666 | +€793,383 | +75.6% |
| Financial debts | 170/4 | €1,022,284 | €1,815,666 | +€793,383 | +77.6% |
| Other amounts payable | 178/9 | €27,000 | €27,000 | = | 0.0% |
| Amounts payable within one year | 42/48 | €83,673 | €186,893 | +€103,220 | +123.4% |
| Current portion of amounts payable after more than one year | 42 | €40,738 | €120,639 | +€79,901 | +196.1% |
| Trade debts | 44 | €5,288 | €1,913 | -€3,375 | -63.8% |
| Suppliers | 440/4 | €5,288 | €1,913 | -€3,375 | -63.8% |
| Taxes, remuneration and social security | 45 | €37,020 | €63,039 | +€26,019 | +70.3% |
| Taxes | 450/3 | €37,020 | €63,039 | +€26,019 | +70.3% |
| Other amounts payable | 47/48 | €627 | €1,302 | +€674 | +107.6% |
| Accrued charges and deferred income | 492/3 | €1,021 | €1,912 | +€891 | +87.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €94,688 | +€94,688 | |
| Other operating charges | 640/8 | €1,299 | €2,292 | +€994 | +76.5% |
| Gross operating margin | 9900 | €79,128 | €200,850 | +€121,722 | +153.8% |
| Operating profit (loss) | 9901 | €77,830 | €103,870 | +€26,040 | +33.5% |
| Financial income | 75/76B | €232,349 | €244,769 | +€12,419 | +5.3% |
| Recurring financial income | 75 | €232,349 | €244,769 | +€12,419 | +5.3% |
| Financial charges | 65/66B | €21,189 | €29,343 | +€8,154 | +38.5% |
| Recurring financial charges | 65 | €21,189 | €29,343 | +€8,154 | +38.5% |
| Profit (loss) for the period before taxes | 9903 | €288,990 | €319,296 | +€30,306 | +10.5% |
| Income taxes | 67/77 | €38,652 | €45,135 | +€6,483 | +16.8% |
| Profit (loss) for the period | 9904 | €250,338 | €274,161 | +€23,823 | +9.5% |
| Profit (loss) for the period to be appropriated | 9905 | €250,338 | €274,161 | +€23,823 | +9.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.